Judith A Anesi1,2, Ebbing Lautenbach1,2,3, Pranita D Tamma4, Kerri A Thom5, Emily A Blumberg1, Kevin Alby6, Warren B Bilker2,3, Alissa Werzen7, Pam Tolomeo2,3, Jacqueline Omorogbe2, Lisa Pineles5, Jennifer H Han8. 1. Division of Infectious Diseases, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA. 2. Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA. 3. Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA. 4. Department of Pediatrics, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. 5. Department of Epidemiology and Public Health, University of Maryland School of Medicine, University of Maryland, Baltimore, Maryland, USA. 6. Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, North Carolina, USA. 7. Division of Infectious Diseases, University of Maryland Medical Center, Baltimore, Maryland, USA. 8. GlaxoSmithKline, Rockville, Maryland, USA.
Abstract
BACKGROUND: Approximately 40% of all Enterobacterales (EB) bloodstream infections (BSIs) among solid organ transplant recipients (SOTRs) are due to extended-spectrum β-lactamase (ESBL)-producing organisms, but risk factors for such infections remain ill defined in this population. We sought to determine the risk factors for ESBL-EB BSIs among SOTRs. METHODS: A multicenter case-control study was performed. All SOTRs with an EB BSI at the Hospital of the University of Pennsylvania and University of Maryland Medical Center between 1 January 2007 and 30 June 2018 and at The Johns Hopkins Hospital between 1 January 2005 and 31 December 2015 were included. Cases were those with an ESBL-EB BSI. Controls were those with a non-ESBL-EB BSI. Multivariable logistic regression was performed to determine risk factors for ESBL-EB BSI. RESULTS: There were 988 episodes of EB BSI, of which 395 (40%) were due to an ESBL-EB. On multivariable analysis, the independent risk factors for ESBL-EB BSI included: ESBL-EB on prior culture (aOR, 12.75; 95% CI, 3.23-50.33; P < .001), a corticosteroid-containing immunosuppression regimen (aOR 1.30; 95% CI 1.03-1.65; P = .030), acute rejection treated with corticosteroids (aOR 1.18; 95% CI 1.16-1.19; P < .001), and exposure to third-generation cephalosporins (aOR 1.95; 95% CI 1.48-2.57; P < .001), echinocandins (aOR 1.61; 95% CI 1.08-2.40; P = .020), and trimethoprim-sulfamethoxazole (aOR 1.35; 95% CI 1.10-1.64; P = .003). CONCLUSIONS: We identified several novel risk factors that are uniquely important to the SOTR population, including exposure to trimethoprim-sulfamethoxazole and corticosteroid-containing immunosuppressive regimens. Further studies exploring these associations and testing interventions aimed at these modifiable risk factors among SOTRs are needed.
BACKGROUND: Approximately 40% of all Enterobacterales (EB) bloodstream infections (BSIs) among solid organ transplant recipients (SOTRs) are due to extended-spectrum β-lactamase (ESBL)-producing organisms, but risk factors for such infections remain ill defined in this population. We sought to determine the risk factors for ESBL-EB BSIs among SOTRs. METHODS: A multicenter case-control study was performed. All SOTRs with an EB BSI at the Hospital of the University of Pennsylvania and University of Maryland Medical Center between 1 January 2007 and 30 June 2018 and at The Johns Hopkins Hospital between 1 January 2005 and 31 December 2015 were included. Cases were those with an ESBL-EB BSI. Controls were those with a non-ESBL-EB BSI. Multivariable logistic regression was performed to determine risk factors for ESBL-EB BSI. RESULTS: There were 988 episodes of EB BSI, of which 395 (40%) were due to an ESBL-EB. On multivariable analysis, the independent risk factors for ESBL-EB BSI included: ESBL-EB on prior culture (aOR, 12.75; 95% CI, 3.23-50.33; P < .001), a corticosteroid-containing immunosuppression regimen (aOR 1.30; 95% CI 1.03-1.65; P = .030), acute rejection treated with corticosteroids (aOR 1.18; 95% CI 1.16-1.19; P < .001), and exposure to third-generation cephalosporins (aOR 1.95; 95% CI 1.48-2.57; P < .001), echinocandins (aOR 1.61; 95% CI 1.08-2.40; P = .020), and trimethoprim-sulfamethoxazole (aOR 1.35; 95% CI 1.10-1.64; P = .003). CONCLUSIONS: We identified several novel risk factors that are uniquely important to the SOTR population, including exposure to trimethoprim-sulfamethoxazole and corticosteroid-containing immunosuppressive regimens. Further studies exploring these associations and testing interventions aimed at these modifiable risk factors among SOTRs are needed.
Authors: M Giannella; M Bartoletti; M C Morelli; S Tedeschi; F Cristini; F Tumietto; E Pasqualini; I Danese; C Campoli; N Di Lauria; S Faenza; G Ercolani; R Lewis; A D Pinna; P Viale Journal: Am J Transplant Date: 2015-03-04 Impact factor: 8.086
Authors: Nina Singh; Marilyn M Wagener; Asia Obman; Thomas V Cacciarelli; Michael E de Vera; Timothy Gayowski Journal: Liver Transpl Date: 2004-07 Impact factor: 5.799
Authors: Jeffrey T Guptill; Vern C Juel; Janice M Massey; Amanda C Anderson; Manisha Chopra; John S Yi; Ehsanollah Esfandiari; Tim Buchanan; Bryan Smith; Paul Atherfold; Emma Jones; James F Howard Journal: Autoimmunity Date: 2016-08-11 Impact factor: 2.815
Authors: G Hoarau; P K Mukherjee; C Gower-Rousseau; C Hager; J Chandra; M A Retuerto; C Neut; S Vermeire; J Clemente; J F Colombel; H Fujioka; D Poulain; B Sendid; M A Ghannoum Journal: mBio Date: 2016-09-20 Impact factor: 7.867
Authors: Philipp Kohler; Aline Wolfensberger; Susanne Stampf; Andreas Brönnimann; Katia Boggian; Christian van Delden; Melody Favre; Cédric Hirzel; Nina Khanna; Stefan P Kuster; Oriol Manuel; Dionysios Neofytos; Silvio Ragozzino; Peter W Schreiber; Laura Walti; Nicolas J Mueller Journal: Antimicrob Resist Infect Control Date: 2021-03-07 Impact factor: 4.887